Karolinska Institutet at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Karolinska Institutet takes part in 3 sessions at CTAD 2026 in Boston. Its program spans prevention, new drugs and real-world care. Its work covers rapamycin effects in early Alzheimer's disease, a tau aggregation disruptor in mice and shingles vaccination and later care needs.

Organization	CTAD 2026 Attendance
Karolinska Institutet Stockholm, Sweden
ki.se Universities & institutes Swedish medical university with large dementia research programmes, including coordination of the World-Wide FINGERS prevention trial network.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue The effect of herpes zoster vaccination on full-time care use in people with and without cognitive complaints: a causal inference study using Swedish record-linkage data (P147) Prevention and early disease · Real-world data and access Poster Wed Nov 18 7:15am–5:30pm STX-03, an Orally Bioavailable Small-Molecule Tau Aggregation Disruptor, Reduces Pathological Tau in the rTg4510 Mouse Model (P328) Anti-amyloid and anti-tau therapies Talk Wed Nov 18 2:55pm Rapamycin modulates disease-relevant processes in the central nervous system of patients with early Alzheimer’s disease: data from PET, MRI and CSF with long-term follow-up Other mechanisms and targets

Organization

CTAD 2026 Attendance

Karolinska Institutet

Stockholm, Sweden

ki.se

Universities & institutes

Swedish medical university with large dementia research programmes, including coordination of the World-Wide FINGERS prevention trial network.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

The effect of herpes zoster vaccination on full-time care use in people with and without cognitive complaints: a causal inference study using Swedish record-linkage data (P147)

Prevention and early disease · Real-world data and access

Poster

Wed Nov 18
7:15am–5:30pm

STX-03, an Orally Bioavailable Small-Molecule Tau Aggregation Disruptor, Reduces Pathological Tau in the rTg4510 Mouse Model (P328)

Anti-amyloid and anti-tau therapies

Talk

Wed Nov 18
2:55pm

Rapamycin modulates disease-relevant processes in the central nervous system of patients with early Alzheimer’s disease: data from PET, MRI and CSF with long-term follow-up

Other mechanisms and targets

Instantly find 20 buyers from Karolinska Institutet

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction